Stock Ratings / Health Care / VCYT / insiders

CDNA (69) CON (68) BLLN (71) ACHC (37) ⌘ Pro Terminal →

Veracyte Inc. (VCYT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$52.17 +3.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Veracyte Inc. (VCYT) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (70% profit margin, 5% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $4.19B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VCYT)Realized 20D OHLCV Swing Band: ±11.3%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

VCYT Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (VCYT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on VCYT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (VCYT Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 1,540+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VCYT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.96%⚡ TESTING RESISTANCE

2026-11-01O $50.31H $52.17L $50.31C $52.17VOL 1.23M

RES: $52.16SUP: $33.39SMA50: $44.62SMA200: $42.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VCYT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VCYT Butterfly Map → + Track VCYT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

42.9%/yr Implied 5Y Growth

vs. +16.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VCYT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VCYT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VCYT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCYT)

Health Care Rank #40 of 188 ⚔️ CDNA vs VCYT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VCYT vs. CDNA, CON, BLLN, ACHC)

Industry: Medical Specialities (20 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Veracyte Inc. (VCYT) ranks #40 by composite RQD confidence (74/100, grade B) and #170 by equity capitalization ($4.19B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and — gross margin. VCYT currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VCYT ACTIVE Veracyte Inc.	B	74/100	63.2x	70.1%	4.6%	+3.70%	$4.19B	Benchmark Subject
CDNA CareDx Inc.	C+	69/100	—	—	-8.2%	-0.85%	$3.70B	/cdna-vs-vcyt →
CON Concentra Group Holdings Parent Inc.	C+	68/100	31.6x	—	19.7%	+1.63%	$5.26B	/con-vs-vcyt →
BLLN BillionToOne Inc.	B-	71/100	—	68.3%	2.9%	+0.74%	$5.42B	/blln-vs-vcyt →
ACHC Acadia Healthcare Company Inc.	D-	37/100	—	—	-24.8%	-0.17%	$2.74B	/achc-vs-vcyt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001384101

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Veracyte Inc. (VCYT) reported GAAP revenue of $517.1M (+16.0% vs. FY2024 revenue of $445.8M , and +43.2% cumulative change since FY2023) , GAAP net income of $66.4M, operating cash flow of $136.3M, and free cash flow of $126.6M (+98.5% YoY). On the balance sheet, VCYT closed FY2025 with $1.41B in total assets against $43.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$517.1M	$66.4M	$136.3M	$126.6M	$1.41B	$43.4M
FY2024 (FY)	2024-12-31	$445.8M	$24.1M	$75.1M	$63.8M	$1.30B	$55.8M
FY2023 (FY)	2023-12-31	$361.1M	-$74.4M	$44.2M	$28.0M	$2.31B	$539.8M

3. VCYT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VCYT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Veracyte Inc. (NASDAQ: VCYT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $52.17 (+3.70% 1D, market cap $4.19B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 11/20. Across 188 tracked Health Care issuers, VCYT ranks #40 in composite RQD confidence.

How does VCYT compare to CDNA and CON in the Health Care sector?

Within the Health Care sector (Medical Specialities), VCYT carries a Roarable B (74/100 RQD), trailing P/E of 63.2x, gross margin of 70.1%, and ROIC of 4.6%. By comparison, CDNA (CareDx Inc.) holds a C+ grade (69/100 RQD, P/E N/A, ROIC -8.2%, cap $3.70B) and CON (Concentra Group Holdings Parent Inc.) posts a C+ grade (68/100 RQD, P/E 31.6x, ROIC 19.7%, cap $5.26B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VCYT?

Per VCYT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001384101), Veracyte Inc. generated $517.1M in revenue (+16.0% YoY), $66.4M in net income, and $126.6M in free cash flow against $1.41B in total assets and $43.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Priced at 63x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VCYT trading relative to its 50-day, 200-day, and 52-week technical levels?

VCYT last traded at $52.17 (+3.70% on volume of 1,231,749 shares), positioning the stock +16.92% above its 50-day simple moving average ($44.62) and +21.67% above its 200-day simple moving average ($42.88). Across its 52-week range of $29.45 to $60.91, VCYT sits at the 72.2% percentile with a 14-day RSI of 65.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.3% ($46.27 to $58.07).

VCYT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are VCYT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies VCYT leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: VCYT RQD Cockpit VCYT 12M Forecast VCYT Earnings & Move VCYT Dividends & DRIP VCYT Insiders & 13F VCYT Whale Options VCYT Profit Sankey VCYT News & Why